Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YMI024 in stable coronary artery disease with elevated hsCRP
NCT07830719Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Sep 2026
- Primary completion
- Aug 2027
- Countries
- 5
01
Overview
A Phase 2 trial of YMI024 in coronary artery disease (CAD), sponsored by Novartis. Started Sep 2026; status: recruiting.
02
Drugs
YMI024
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07830719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07830719.